Pyxis Oncology(US:PYXS)2024-08-14 20:19Financial Position - As of June 30, 2024, Pyxis Oncology had cash and cash equivalents totaling $157.2 million, expected to fund operations into the second half of 2026[6]. - Total assets as of June 30, 2024, were $208.4 million, an increase from $173.7 million at the end of 2023[11]. - The outstanding number of shares of common stock as of August 14, 2024, was 58,942,243[7]. Revenue and Expenses - Total revenues for the six months ended June 30, 2024, were $16.1 million, primarily from royalty revenues and the sale of royalty rights[10]. - Research and development expenses for Q2 2024 were $13.9 million, up from $11.4 million in Q2 2023, primarily due to increased clinical trial-related expenses[6]. - General and administrative expenses decreased to $6.1 million in Q2 2024 from $6.7 million in Q2 2023[7]. - The net loss for Q2 2024 was $17.3 million, or ($0.29) per common share, compared to a net loss of $15.9 million, or ($0.41) per common share, in Q2 2023[7]. Clinical Trials - A total of 72 subjects have been dosed in the ongoing Phase 1 trial of PYX-201, focusing on various difficult-to-treat cancers[3]. - The company expects to announce preliminary data from the Phase 1 trial of PYX-201 in fall 2024, including efficacy and safety results[4]. - PYX-106, another clinical candidate, has dosed 33 subjects in its Phase 1 trial, with preliminary data expected by year-end 2024[5].